Glanzmann’s disease, also called Glanzmann thrombasthenia, is a rare inherited bleeding disorder that affects the body’s ability to form blood clots properly, leading to easy bruising and prolonged bleeding episodes throughout a person’s life.
Epidemiology
Glanzmann thrombasthenia is considered extremely rare in the general population. Medical experts estimate that approximately one in every one million people worldwide are born with this condition. This makes it one of the rarest bleeding disorders currently known to medicine.[1][2]
However, the frequency of this disease varies significantly across different populations and communities. In certain groups where marriages between close relatives are more common, the prevalence is notably higher. In these communities, the rate can reach approximately one in every 200,000 people. This increased frequency is observed in specific regions including certain countries in the Middle East, the Canadian provinces of Newfoundland and Labrador, and the Romani community in France, particularly among the French Manouche people.[1][2]
The disorder affects males and females equally, since it is not linked to sex chromosomes. Studies show that females may be identified slightly more frequently than males, possibly because women experience symptoms related to menstrual bleeding that prompt medical evaluation. The condition is most commonly diagnosed in childhood and young adults, although it can be identified at any age depending on the severity of symptoms.[2]
Some people with very mild symptoms may never be formally diagnosed with Glanzmann thrombasthenia, which means the actual number of affected individuals could be higher than what is currently reported in medical literature.[2]
Causes
Glanzmann thrombasthenia is primarily caused by inherited genetic mutations that affect how blood platelets function. The disease occurs when there are mutations in specific genes called ITGA2B or ITGB3. These genes contain the instructions for making a protein complex known as integrin alpha IIb/beta 3, which was previously referred to as glycoprotein IIb/IIIa. This protein is essential because it acts as a receptor on the surface of platelets, allowing them to bind to fibrinogen, a substance necessary for forming blood clots.[1][2]
These two genes are located close together on chromosome 17. More than 100 different mutations have been reported in these genes, and any of them can lead to Glanzmann thrombasthenia. The mutations either reduce the amount of this important protein or cause it to function improperly. When the integrin alpha IIb/beta 3 protein is absent, reduced, or not working correctly, platelets cannot aggregate or stick together properly. Without proper platelet aggregation, blood clots form much more slowly than normal, resulting in prolonged bleeding.[2][4]
The disease follows an autosomal recessive pattern of inheritance. This means that a person must inherit a mutated gene from both parents to develop the condition. Each parent carries one copy of the mutated gene but also has one normal gene, which is why they typically do not show symptoms themselves. These parents are called carriers. When both parents are carriers, they have a 25 percent chance with each pregnancy of having a child with Glanzmann thrombasthenia.[1][5]
In extremely rare cases, some people develop what is called acquired Glanzmann thrombasthenia later in life. This is not inherited but occurs when the body’s immune system mistakenly produces antibodies that attack the integrin alpha IIb/beta 3 protein. Various medical conditions and some medications can potentially trigger this immune response. Despite these rare acquired cases, medical experts still classify Glanzmann thrombasthenia primarily as an inherited bleeding disorder.[1][2]
Risk Factors
The primary risk factor for developing Glanzmann thrombasthenia is having two parents who both carry the mutated gene. This risk is significantly higher in communities where marriages between relatives are common, a practice known as consanguinity. In such populations, the likelihood that both parents carry the same genetic mutation increases substantially, raising the chances of having a child with the disorder.[2]
Specific ethnic and geographic populations have a higher prevalence of the carrier status for Glanzmann thrombasthenia. These include people from Pakistan, certain Middle Eastern countries, the Canadian provinces of Newfoundland and Labrador, and members of the Romani community, particularly in France. Individuals from these backgrounds may be at increased risk of either being carriers or having the disease.[1][2]
Having a family history of the condition, particularly an older sibling with Glanzmann thrombasthenia, is another important risk factor. When one child in a family has been diagnosed with the disease, there is a known risk that future children could also inherit the condition if both parents are carriers.[6]
Symptoms
People with Glanzmann thrombasthenia experience a range of bleeding symptoms that can vary significantly in severity from person to person, even within the same family. The hallmark of this condition is that bleeding tends to be more prolonged than normal following an injury, or it may occur spontaneously without any clear triggering event.[1][5]
One of the most common and noticeable symptoms is easy bruising. People with this condition develop bruises much more readily than others, often from minor bumps or knocks that would not typically cause bruising. These bruises can appear as purple spots or patches on the skin, known as purpura, or as smaller purple, brown, or red dots called petechiae. The extensive bruising can be so prominent that it sometimes leads to concerns about abuse, particularly in children.[1][3]
Bleeding from the mucous membranes is particularly characteristic of Glanzmann thrombasthenia. This includes frequent and often prolonged nosebleeds, which medical professionals call epistaxis. These nosebleeds can be difficult to stop and may require medical attention. People with the condition also commonly experience bleeding gums, especially during tooth brushing or dental procedures. Bleeding in the mouth and gums can be both troublesome and embarrassing for affected individuals.[1][3]
For women and girls with Glanzmann thrombasthenia, heavy menstrual bleeding, medically termed menorrhagia, is a significant problem. Periods can be unusually heavy and prolonged, causing considerable distress and disruption to daily activities. This excessive menstrual bleeding can also lead to other complications such as iron deficiency and anemia over time.[1][3]
Some individuals experience bleeding in the gastrointestinal tract, which can occur anywhere along the digestive system. This type of bleeding typically happens later in life and affects about one-quarter of individuals with the condition. While less common, bleeding after surgery or dental work can be severe and potentially life-threatening if not properly managed. Increased bleeding during and after childbirth is another serious concern for women with this disorder.[4][5]
It is important to note that internal bleeding, such as bleeding inside the skull (intracranial hemorrhage) or into joints (hemarthrosis), is much less common in Glanzmann thrombasthenia compared to other bleeding disorders like hemophilia. Most bleeding in this condition occurs from the skin or mucous membranes rather than deep within the body.[1][3]
Many people with Glanzmann thrombasthenia also experience persistent fatigue. This tiredness results from chronic anemia due to frequent bleeding episodes and the constant mental burden of having to plan ahead and worry about potential bleeding situations. The combination of physical blood loss and psychological stress significantly impacts quality of life for many affected individuals.[18]
Prevention
While Glanzmann thrombasthenia itself cannot be prevented because it is an inherited genetic condition, several measures can help reduce the frequency and severity of bleeding episodes. These preventive strategies focus on avoiding situations that might trigger bleeding and maintaining overall health.
One of the most important preventive measures is avoiding medications that can interfere with platelet function. People with Glanzmann thrombasthenia should strictly avoid aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. These common pain relievers can further impair platelet function and increase the risk of bleeding. Healthcare providers should always be informed about the diagnosis so they can prescribe alternative pain medications that are safe to use.[3][4]
Maintaining good dental hygiene is crucial for preventing bleeding from the gums. Regular tooth brushing with a soft-bristled toothbrush, flossing gently, and routine dental check-ups can help minimize gum disease and reduce the likelihood of gum bleeding. People with this condition should inform their dentist about their diagnosis before any dental procedures.[3]
For women with heavy menstrual bleeding, hormonal therapy such as birth control pills may be recommended. These medications can help reduce the heaviness and duration of menstrual periods, thereby preventing excessive blood loss and the development of anemia.[11]
Iron and folate supplementation may be necessary for people who experience frequent bleeding episodes. These supplements help prevent or treat anemia, which is a common complication of chronic blood loss. Maintaining adequate iron stores supports the body’s ability to produce red blood cells and helps combat the fatigue associated with anemia.[4]
Vaccination against hepatitis B is recommended for all people with Glanzmann thrombasthenia. This preventive measure is important because individuals with bleeding disorders may require multiple blood product transfusions throughout their lives, which carries a risk of bloodborne infections. Protecting against hepatitis B through vaccination reduces this infectious disease risk.[4][7]
Families with a history of Glanzmann thrombasthenia or known carrier status may benefit from genetic counseling. This service can help prospective parents understand their risk of having a child with the condition and explore options such as genetic testing during pregnancy.[5]
Pathophysiology
Understanding how Glanzmann thrombasthenia affects the body requires knowledge of the normal blood clotting process. When a blood vessel is injured, the body responds by forming a clot to stop the bleeding. Platelets, which are tiny cell fragments circulating in the blood, play a central role in this process. These platelets rush to the site of injury and stick together to form a temporary plug that seals the damaged vessel.[8]
The key to platelet aggregation is a protein complex on the platelet surface called integrin alpha IIb/beta 3. This protein is made up of two parts: the alpha IIb subunit (coded by the ITGA2B gene) and the beta 3 subunit (coded by the ITGB3 gene). These two parts come together to form a receptor that can recognize and bind to fibrinogen, a protein dissolved in the blood. Under normal circumstances, when platelets are activated by signals from the damaged blood vessel, the integrin alpha IIb/beta 3 protein changes its shape into an active form that can grab onto fibrinogen molecules.[2][4]
Fibrinogen acts like a bridge between platelets. One fibrinogen molecule can bind to the integrin alpha IIb/beta 3 receptor on one platelet and simultaneously to the same receptor on another platelet. This cross-linking allows many platelets to stick together, forming the platelet plug that is essential for stopping blood loss. Additionally, this protein complex can also bind to other substances such as von Willebrand factor, fibronectin, and vitronectin, all of which contribute to effective blood clotting.[3][4]
In people with Glanzmann thrombasthenia, genetic mutations cause a problem with the integrin alpha IIb/beta 3 protein. Depending on the specific mutation, the body may produce little or no protein, or it may produce a protein that does not work properly. The severity of the condition is often classified into three types based on the amount and function of the integrin protein present on platelets.[5]
Type I Glanzmann thrombasthenia, which is the most common form, occurs when less than 5 percent of normal integrin alpha IIb/beta 3 levels are present on platelets. Type II is characterized by having between 5 and 20 percent of normal protein levels. Type III, also called the variant type, is unusual because adequate amounts of the protein are present, but it simply does not function correctly. Regardless of the type, the result is the same: platelets cannot effectively bind to fibrinogen and therefore cannot aggregate properly.[5][10]
When platelets fail to aggregate, the initial platelet plug that forms at the site of injury is weak and unstable. While platelet numbers and appearance under the microscope are completely normal in people with Glanzmann thrombasthenia, their function is severely impaired. This functional defect means that even though there are plenty of platelets circulating in the blood, they cannot do their job of forming a solid clot. Consequently, bleeding continues for much longer than it would in someone with normally functioning platelets.[2][4]
Laboratory tests can demonstrate this functional abnormality. When platelets from a person with Glanzmann thrombasthenia are tested with various substances that normally trigger platelet aggregation—such as adenosine diphosphate (ADP), thrombin, collagen, or epinephrine—the platelets fail to clump together. However, they do respond normally to a substance called ristocetin, which triggers a different type of platelet response. This specific pattern of test results helps doctors distinguish Glanzmann thrombasthenia from other platelet disorders.[3][4]
Interestingly, the amount of integrin alpha IIb/beta 3 protein present on platelets does not always predict how severely a person will bleed. Some individuals with virtually undetectable levels of the protein experience only mild bleeding symptoms, while others with 10 to 15 percent of normal levels may have severe bleeding. This suggests that other factors, which have not yet been fully identified, also play important roles in determining bleeding severity.[3]
Understanding the role of integrin alpha IIb/beta 3 in Glanzmann thrombasthenia has had important implications beyond this rare disease. Medical researchers have used this knowledge to develop a class of medications called integrin alpha IIb/beta 3 inhibitors. These drugs intentionally block this receptor in people who are at risk of forming dangerous blood clots, such as during heart attacks. This is an example of how studying rare diseases can lead to advances in treating more common conditions.[3][4]
